Hepatitis Medicine

• Used for treatment of Hepatitis C Virus injection
• Higher cure rate other antiviral drugs
• Longer shelf life

• Brand Name : Sofovir
• Generic Name : Sofosbuvir
• Company : Hetero
• Strength : 400mg
• Packing : Pack of 28 Tablets
• Type : Tablets

• Sofovir is a prescription drug and should be used under proper medical guidance and advice..

• Item Code: Sofovir

• Effective against cancer
• Longer shelf life
• Compositional accuracy

• Used for treatment of Hepatitis C Virus injection
• Higher cure rate other antiviral drugs
• Longer shelf life

sofosbuvir is an antiviral medication that prevents hepatitis C virus (HCV) cells from multiplying in your body.

is used in combination with other medications to treat hepatitis C in adults. Sofosbuvir is sometimes used in people who also have HIV, or people who have liver cancer and are going to have a liver transplant. This medicine is not a treatment for HIV or AIDS.

must be given in combination with other antiviral medications and should not be used alone. is usually given with ribavirin with or without peginterferon alfa

is also used together with Daclatasvir to treat hepatitis C genotype 3 infection in adults.

You should not use you are allergic to sofosbuvir.

To make sure is safe for you, tell your doctor if you have:

• liver problems other than hepatitis, or if you have had a liver transplant;

• kidney disease (or if you are on dialysis);

• HIV (human immunodeficiency virus); or

• if you have recently used a heart rhythm medicine called .

is used in combination with ribavirin. Ribavirin can cause birth defects or death in an unborn baby. You may need to have a negative pregnancy test before using these medications together, and every month during your treatment.

• If you are a woman, do not use with ribavirin if you are pregnant.

• If you are a man, do not use this drug combination if your partner is pregnant. An unborn baby could also be harmed if a man fathers the child while he is taking ribavirin.

• Use at least 2 effective forms of non hormonal birth control (, diaphragm with spermicide) while either partner is using these medications together. Keep using 2 forms of birth control for at least 6 months after treatment ends. Tell your doctor right away if a pregnancy occurs while either the mother or the father is using with ribavirin.

It is not known whether sofosbuvir passes into breast milk or if it could harm a nursing baby. You should not breast-feed while using this medicine.

400 mg orally once a day

Recommended Regimens:
-Genotype 1 or 4 chronic hepatitis C (CHC): , peginterferon alfa, and ribavirin
-Genotype 2 CHC: and ribavirin
-Genotype 3 CHC: and ribavirin
-Hepatocellular carcinoma awaiting liver transplantation: and ribavirin

Duration of Therapy:
-Genotype 1 or 4 CHC: 12 weeks
-Genotype 2 CHC: 12 weeks
-Genotype 3 CHC: 24 weeks
-Hepatocellular carcinoma awaiting liver transplantation: Up to 48 weeks or until time of liver transplantation (whichever occurs first)

Comments:
-Sofosbuvir should be used in combination with ribavirin or with pegylated and ribavirin.
-Efficacy was established in patients with HCV genotype 1, 2, 3, or 4 infection, including patients with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and HCV/HIV-1 coinfected patients.
-and ribavirin therapy for 24 weeks can be considered for patients with genotype 1 CHC who cannot use an -based regimen; treatment decision should be guided by benefits/risks assessment for the individual patient.
-and ribavirin therapy is recommended for patients with hepatocellular carcinoma awaiting liver transplantation to prevent posttransplant HCV reinfection.

Approved indication: As a part of a combination antiviral treatment regimen, for the treatment of chronic hepatitis C infection

Daclatasvir is a drug for the treatment of hepatitis C (HCV). It is approved for Hepatitis C genotype 3 infections.

Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.

Daclatasvir has been tested in combination regimens with pegylated interferonand ribavirin,as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.

• Anti infectious
• Anti-bacterial
• Highly effective

• Therapy-naive patients without cirrhosis: 12 weeks; 8 weeks can be considered if pretreatment HCV RNA less than 6 million international units/mL
• Therapy-naive patients with cirrhosis: 12 weeks
• Therapy-experienced patients without cirrhosis: 12 weeks
• Therapy-experienced patients with cirrhosis: 24 weeks

• Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.
• Therapy-experienced patients are those patients who have failed treatment with either peginterferon alfa/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor.

Mydacla (Daclatasvir) is a drug for the treatment of hepatitis C (HCV). It is approved for Hepatitis C genotype 3 infections.

Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.

Daclatasvir has been tested in combination regimens with pegylated interferonand ribavirin,as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.

Natdac (Daclatasvir) is a drug for the treatment of hepatitis C (HCV). it is approved for Hepatitis C genotype 3 infections.

Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.

Daclatasvir has been tested in combination regimens with pegylated interferonand ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.

• Anti infectious
• Anti-bacterial
• Highly effective

• Therapy-naive patients without cirrhosis: 12 weeks; 8 weeks can be considered if pretreatment HCV RNA less than 6 million international units/mL
• Therapy-naive patients with cirrhosis: 12 weeks
• Therapy-experienced patients without cirrhosis: 12 weeks
• Therapy-experienced patients with cirrhosis: 24 weeks

• Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.
• Therapy-experienced patients are those patients who have failed treatment with either peginterferon alfa/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor.

Sofovir Tablets

Drug Name:- Sofosbuvir

Strength:- 400mg

Packing:- Pack of 28 Tablet

Uses:- Sofovir 400mg Tablet containing the active ingredient sofosbuvir is a nucleotide polymerase inhibitor type of antiviral medication used to treat Hepatitis C. Sofovir Tablets must be used in combination with other antiviral medicines to reduce the amount of hepatitis C virus (HCV) in the body to help the liver recover. Chronic hepatitis C infections can cause serious liver problems such as liver cancer or cirrhosis (scarring). Patients with HIV or liver cancer and are going to have a liver transplant may also use the drug to decrease the risk of reinfection after the transplant.

Side Effects :- Nausea, Diarrhea, Headaches, Loss of appetite, Lower back or side pain, Insomnia,Fever.

Other Information

• Minimum Order Quantity: 01 Piece
• Port of Dispatch: Mumbai
• Production Capacity: 50 to 150
• Delivery Time: 5 to 7 working day for out of India
• Packaging Details: Bottle Packing

Other Information

• Minimum Order Quantity: 05 Piece
• Port of Dispatch: Mumbai
• Production Capacity: 500 to 1000
• Delivery Time: 5 to 7 working day for out of India
• Packaging Details: Bottle Packing

Other Information

• Minimum Order Quantity: 05 Piece
• Port of Dispatch: Mumbai
• Production Capacity: 500 to 1000
• Delivery Time: 5 to 7 working day for out of India
• Packaging Details: Bottle Packing

Daclafab (Daclatasvir) is a drug for the treatment of hepatitis C (HCV). It is approved for Hepatitis C genotype 3 infections.

Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.

Daclatasvir has been tested in combination regimens with pegylated interferonand ribavirin,as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.

Hepcdac (Daclatasvir) is a drug for the treatment of hepatitis C (HCV). It is approved for Hepatitis C genotype 3 infections.

Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA.

Daclatasvir has been tested in combination regimens with pegylated interferonand ribavirin,as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir.

• Optimum and safe results
• Long shelf life
• Precisely processed

• Anti infectious
• Anti-bacterial
• Highly effective

• Therapy-naive patients without cirrhosis: 12 weeks; 8 weeks can be considered if pretreatment HCV RNA less than 6 million international units/mL
• Therapy-naive patients with cirrhosis: 12 weeks
• Therapy-experienced patients without cirrhosis: 12 weeks
• Therapy-experienced patients with cirrhosis: 24 weeks

• Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.
• Therapy-experienced patients are those patients who have failed treatment with either peginterferon alfa/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor.

• Anti infectious
• Anti-bacterial
• Highly effective

• Therapy-naive patients without cirrhosis: 12 weeks; 8 weeks can be considered if pretreatment HCV RNA less than 6 million international units/mL
• Therapy-naive patients with cirrhosis: 12 weeks
• Therapy-experienced patients without cirrhosis: 12 weeks
• Therapy-experienced patients with cirrhosis: 24 weeks

• Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.
• Therapy-experienced patients are those patients who have failed treatment with either peginterferon alfa/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor.

• Anti infectious
• Anti-bacterial
• Highly effective

• Therapy-naive patients without cirrhosis: 12 weeks; 8 weeks can be considered if pretreatment HCV RNA less than 6 million international units/mL
• Therapy-naive patients with cirrhosis: 12 weeks
• Therapy-experienced patients without cirrhosis: 12 weeks
• Therapy-experienced patients with cirrhosis: 24 weeks

• Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.
• Therapy-experienced patients are those patients who have failed treatment with either peginterferon alfa/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor.

Drug Name:- Sofosbuvir

Strength:- 400mg

Packing:- Pack of 28 Tablet

Uses:- Sofosbuvir 400mg Tablet containing the active ingredient sofosbuvir is a nucleotide polymerase inhibitor type of antiviral medication used to treat Hepatitis C. Sofosbuvir Tablets must be used in combination with other antiviral medicines to reduce the amount of hepatitis C virus (HCV) in the body to help the liver recover. Chronic hepatitis C infections can cause serious liver problems such as liver cancer or cirrhosis (scarring). Patients with HIV or liver cancer and are going to have a liver transplant may also use the drug to decrease the risk of reinfection after the transplant.

Side Effects :- Nausea, Diarrhea, Headaches, Loss of appetite, Lower back or side pain, Insomnia,Fever.

• Anti infectious
• Anti-bacterial
• Highly effective

• Therapy-naive patients without cirrhosis: 12 weeks; 8 weeks can be considered if pretreatment HCV RNA less than 6 million international units/mL
• Therapy-naive patients with cirrhosis: 12 weeks
• Therapy-experienced patients without cirrhosis: 12 weeks
• Therapy-experienced patients with cirrhosis: 24 weeks

• Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.
• Therapy-experienced patients are those patients who have failed treatment with either peginterferon alfa/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor.

X-Vir (Entecavir) is used as an antiviral treatment for patients suffering from a chronic hepatitis B infection. It is classified as a nucleoside analog, and it works by stopping the spread of the virus. Because it can inhibit an enzyme called viral DNA polymerase, it is able to prevent the spread and proliferation of the virus. This can help to reduce the overall amount of the virus present in the body, while also helping to lessen damage to the liver.

X-Vir (Entecavir) is administered orally. It comes as either 0.5mg or 1mg strength tablets. Your physician will be responsible for deciding the right dosage. Adults treating hepatitis B who are deemed to be nucleoside therapy naive may be directed to take 0.5mg once per day. However, some patients may be directed to take 1mg per day (usually in cases of mutations of the virus that are resistance to lamivudine or otherwise difficult to treat). Patients must strictly comply with the instructions given by their physician.

The use of X-Vir (Entecavir) could cause side effects. Tell the physician providing medical care if this happens. Some possible examples are given here:

• Diarrhea
• Headaches
• Digestive discomfort
• Sleepy or fatigued feeling
• Nausea, possibly resulting in vomiting

Although the majority of side effects caused by this medicine are less serious in nature, there is a possibility that some patients will be affected by reactions which are significantly more serious. You must attend the hospital or see your physician straight away if you are affected by coldness, persistent vomiting, feeling weak or any other serious side effects not mentioned here.

Serious conditions including hepatomegaly and lactic acidosis are known to have occurred in some patients treated with X-Vir (Entecavir) for their condition. Discuss this with your physician before starting therapy.

This medication will not cure the infection, and you will need continuous medical treatment in order to manage your condition.

• Effective treats Hepatitis C Virus injection
• Precise pH value
• Excellent cure rate as compared to other antiviral drugs

• Effective treats Hepatitis C Virus injection
• Precise pH value
• Excellent cure rate as compared to other antiviral drugs

• Long shelf life
• Effective
• Highly pure

• Optimum and safe results
• Long shelf life
• Precisely processed

• Dissolves quickly
• Ensures purity
• Anti bacterial

• Therapy-naive patients without cirrhosis: 12 weeks; 8 weeks can be considered if pretreatment HCV RNA less than 6 million international units/mL
• Therapy-naive patients with cirrhosis: 12 weeks
• Therapy-experienced patients without cirrhosis: 12 weeks
• Therapy-experienced patients with cirrhosis: 24 weeks

• Relapse rates are affected by baseline host and viral factors and differ between durations of therapy for some subgroups.
• Therapy-experienced patients are those patients who have failed treatment with either peginterferon alfa/ribavirin or peginterferon alfa/ribavirin/HCV protease inhibitor.

• Long shelf life
• Effective
• Highly pure

Other Information

• Minimum Order Quantity: 3 Bottle(s)
• Production Capacity: 1000 Pieces
• Delivery Time: 3-4 days
• Packaging Details: 28 Tablets in a bottle

E-hep offers hope that you can put hepatitis C (Hep C) behind you.

E-hep is a prescription medicine used with other antiviral medicines

to treat chronic (lasting a long time) hepatitis C genotype 1, 2, 3, or

4 infection in adults.

Other Details:

· Strength: 400 mg

· Packaging: 28 tablets

Use pirfenidone as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• An extra patient leaflet is available with pirfenidone. Talk to your pharmacist if you have questions about this information.
• Take pirfenidone by mouth with food.
• Pirfenidone works best if it is taken at the same time each day.
• If you miss a dose of pirfenidone, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
• If you miss 14 or more days of pirfenidone, call your doctor to find out what to do.

Ask your health care provider any questions you may have about how to use pirfenidone.

Resof Tablets Specifications:

• Brand name : Resof
• Active ingredient : Sofosbuvir
• Marketed by : Dr. Reddy’s Laboratories
• Form: Tablets
• Strength: 400 mg
• Packing: Pack of 28 tablets

Other Information

• Minimum Order Quantity: 10 Piece
• Port of Dispatch: Mumbai
• Production Capacity: 500 to 1000
• Delivery Time: 5 to 7 working day for out of India
• Packaging Details: Bottle packing

• Optimum and safe results
• Long shelf life
• Precisely processed